Xilio Therapeutics, Inc. (XLO) scores 69 out of 100 on boothcheck's 11-model valuation framework. Verdict: Fair The estimated fair value is 15.15, representing a 81% margin of safety. Quantitative score: 62/100. Qualitative score: 90/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.